IPSEN (OTCMKTS:IPSEY – Get Free Report) rose 7.5% during mid-day trading on Friday . The stock traded as high as $48.1850 and last traded at $48.1850. 169 shares were traded during trading, a decline of 92% from the average daily volume of 2,113 shares. The stock had previously closed at $44.81.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.
Get Our Latest Report on IPSEY
IPSEN Stock Up 6.9%
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Stories
- Five stocks we like better than IPSEN
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
